Picture of Mesa Laboratories logo

MLAB — Mesa Laboratories News Story

0.000.00%
us flag iconLast trade - 00:00
HealthcareAdventurousMid CapHigh Flyer

Mesa Labs Q2 revenue up 5%

Overview

Mesa Laboratories fiscal Q2 revenue grows 5%, operating income rises 34.7%

Net income for fiscal Q2 decreases 27.8% compared to prior year

Biopharmaceutical Development and Calibration Solutions show strong growth despite CG challenges

Outlook

Mesa expects sequential revenue growth in 3Q26

Company plans to reinvest $0.9M savings into SDC for long-term growth

Mesa anticipates continued revenue declines in China for FY26

Result Drivers

BPD GROWTH - Biopharmaceutical Development division saw strong revenue growth driven by higher sales of Peptides instruments and delayed bookings from 1Q26

COST REDUCTIONS - Mesa reduced annualized costs by $3.2M to align with global tariffs and currency headwinds, with $2.1M reductions in CG

CG CHALLENGES - Clinical Genomics division faced a 58% revenue decline in China due to macroeconomic and regulatory headwinds

Key Details

MetricBeat/MissActualConsensus Estimate
Q2 EPS$0.45
Q2 Net Income$2.48 mln
Q2 Basic EPS$0.45
Q2 Gross Profit$37.33 mln
Q2 Operating Expenses$32.61 mln
Q2 Operating Income$4.72 mln
Analyst Coverage The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 1 "strong buy" or "buy", 2 "hold" and no "sell" or "strong sell" The average consensus recommendation for the medical equipment, supplies & distribution peer group is "buy" Wall Street's median 12-month price target for Mesa Laboratories Inc is $88.50, about 16.2% above its November 5 closing price of $74.20 The stock recently traded at 45 times the next 12-month earnings vs. a P/E of 40 three months ago Press Release: ID:nGNXfPL84 For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com. (This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

Recent news on Mesa Laboratories

See all news